Floatz logo

435 assets in Melanoma

Therapeutic assets addressing Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
hlx17
Melanoma
Shanghai Henlius BiotechP1C (37)
hlx18
Melanoma
Shanghai Henlius BiotechP1C (37)
Humanized Immunoglobulin G1-Kappa Anti-(Human Cd8) Fused At The C-Terminus Of One Heavy Chain, Via Peptide Linker <Sup>449</Sup> Sggggsggggsggggs<Sup>464</Sup>, To A Variant Of Human Interleukin-2, Glycoform Alfa
Melanoma
Asher Biotherapeutics, Inc.P1C (37)
Idov-Immune
Melanoma
ViroMissile, Inc.P1C (37)
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer
Melanoma
Toray Industries, IncP1C (37)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Tnfrsf4 (Tumor Necrosis Factor Receptor (Tnfr) Superfamily Member 4, Ox40, Cd134)], Homo Sapiens Monoclonal Antibody
Melanoma
HiFiBiO TherapeuticsP1C (37)
Ivonescimab
Melanoma
Peking University Cancer Hospital & InstituteP1C (37)
Jsi-1187
Melanoma
JS InnoPharm, LLCP1C (37)
ln-144
Melanoma
James Isaacs, MDP1C (37)
Loperamide
Melanoma
M.D. Anderson Cancer CenterP1C (37)
lyl845
Melanoma
Lyell Immunopharma, Inc.P1C (37)
mb097
Melanoma
Microbiotica LtdP1C (37)
Mem-288 Intratumoral
Melanoma
Memgen, Inc.P1C (37)
MGC026
Melanoma
MacroGenicsP1C (37)
Modified Vaccinia Virus Ankara Vaccine Expressing P53
Melanoma
City of Hope Medical CenterP1C (37)
mq719
Melanoma
Memorial Sloan Kettering Cancer CenterP1C (37)
mt-8421
Melanoma
Molecular Templates, Inc.P1C (37)
Naptumomab Estafenatox
Melanoma
NeoTX Therapeutics Ltd.P1C (37)
Neovax
Melanoma
Dana-Farber Cancer InstituteP1C (37)
ngm438
Melanoma
NGM Biopharmaceuticals, IncP1C (37)
ngm831
Melanoma
NGM Biopharmaceuticals, IncP1C (37)
nm1f
Melanoma
Hefei TG ImmunoPharma Co., Ltd.P1C (37)
Nst-628
Melanoma
Nested Therapeutics, IncP1C (37)
Optimized Neoantigen Synthetic Long Peptide Vaccine
Melanoma
Washington University School of MedicineP1C (37)
pf-07263689
Melanoma
PfizerP1C (37)
pf-07329640
Melanoma
PfizerP1C (37)
pf-07799544
Melanoma
PfizerP1C (37)
pf-07820435
Melanoma
PfizerP1C (37)
pf-07921585
Melanoma
PfizerP1C (37)
pf-08046032
Melanoma
PfizerP1C (37)
r-5780
Melanoma
Rise Therapeutics LLCP1C (37)
RC198
Melanoma
RemeGen Co., Ltd.P1C (37)
Second Generation 4-1Bbζ B7H3-Egfrt-Dhfr
Melanoma
Seattle Children's HospitalP1C (37)
Second Generation 4-1Bbζ Egfr806-Egfrt And A Second Generation 4 1Bbζ Cd19-Her2Tg
Melanoma
Seattle Children's HospitalP1C (37)
Super1 Tcr-T
Melanoma
Guangzhou FineImmune Biotechnology Co., LTD.P1C (37)
Tasadenoturev
Melanoma
M.D. Anderson Cancer CenterP1C (37)
Tbi-1301
Melanoma
University Health Network, TorontoP1C (37)
Tilt-123
Melanoma
TILT Biotherapeutics Ltd.P1C (37)
tqb2618
Melanoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.P1C (37)
Tsc-200-A0201
Melanoma
TScan Therapeutics, Inc.P1C (37)
Tsc-201-B0702
Melanoma
TScan Therapeutics, Inc.P1C (37)
Tsc-202-A0201
Melanoma
TScan Therapeutics, Inc.P1C (37)
Tsc-203-A0201
Melanoma
TScan Therapeutics, Inc.P1C (37)
Tsc-204-A0101
Melanoma
TScan Therapeutics, Inc.P1C (37)
Tsc-204-A0201
Melanoma
TScan Therapeutics, Inc.P1C (37)
Tsc-204-C0702
Melanoma
TScan Therapeutics, Inc.P1C (37)
Vsv-02
Melanoma
The First Affiliated Hospital of Xinxiang Medical CollegeP1C (37)
Anti-Pd-L1 Monoclonal Antibody Ck-301
Melanoma
Checkpoint Therapeutics, Inc.P1C (36)
Immunoglobulin G1, Anti-(Human Programmed Death-Ligand 1) (Human Monoclonal Sti-3031 .Gamma.1-Chain), Disulfide With Human Monoclonal Sti-3031 .Lambda.-Chain, Dimer
Melanoma
Mayo ClinicP1C (36)
Pimasertib
Melanoma
Day One Biopharmaceuticals, Inc.P1C (36)
Showing 351 to 400 of 435 assets
PreviousPage 8 of 9Next